Detalhe da pesquisa
1.
Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma.
N Engl J Med
; 384(9): 829-841, 2021 03 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33657295
2.
Comparison of weekly and daily recall of pain as an endpoint in a randomized phase 3 trial of cabozantinib for metastatic castration-resistant prostate cancer.
Clin Trials
; 18(4): 408-416, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-33884929
3.
Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma.
N Engl J Med
; 373(19): 1814-23, 2015 Nov 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-26406150
4.
Volumetric response quantified using T1 subtraction predicts long-term survival benefit from cabozantinib monotherapy in recurrent glioblastoma.
Neuro Oncol
; 20(10): 1411-1418, 2018 09 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-29660005
5.
Baseline pretreatment contrast enhancing tumor volume including central necrosis is a prognostic factor in recurrent glioblastoma: evidence from single and multicenter trials.
Neuro Oncol
; 19(1): 89-98, 2017 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27580889
6.
Diffusion MRI Phenotypes Predict Overall Survival Benefit from Anti-VEGF Monotherapy in Recurrent Glioblastoma: Converging Evidence from Phase II Trials.
Clin Cancer Res
; 23(19): 5745-5756, 2017 Oct 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28655794
7.
Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody.
Int J Radiat Oncol Biol Phys
; 58(3): 984-90, 2004 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-14967460